CIK 0001479419
- Non-accelerated filer
- Smaller reporting company
KALA BIO, Inc.
Sign in to watch- Ticker
- KALA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 270604595
- Phone
- +1 781-996-5252
- Business address
- 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476
- Former names
- KALA BIO, Inc., Kala Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 46 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-06-17 | Shah Rajeev M. Director | Grant or award | +20,000 | 20,000 | ||
| 2021-06-17 | Rosen Howard B Director | Grant or award | +20,000 | 44,824 | ||
| 2021-06-17 | PERRY GREGORY D Director | Grant or award | +20,000 | 40,000 | ||
| 2021-06-17 | Paull Robert Bradley Director | Grant or award | +20,000 | 40,000 | ||
| 2021-06-17 | KOVEN ANDREW I Director | Grant or award | +25,000 | 53,000 | ||
| 2021-06-17 | Grunberg Gregory Director | Grant or award | +20,000 | 40,000 | ||
| 2021-04-01 | RA CAPITAL MANAGEMENT, L.P. Director | Other acquisition | +279,846 | $6.74 | $1.9M | 279,846 |
| 2021-04-01 | RA CAPITAL MANAGEMENT, L.P. Director | Other acquisition | +1,407,863 | $6.74 | $9.5M | 10,594,767 |
| 2021-03-01 | Chen Hongming Chief Scientific Officer | Exercise or conversion | +9,500 | $2.30 | $22K | 243,015 |
| 2021-03-01 | Chen Hongming Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy | −9,500 | 53,736 | ||
| 2021-02-25 | Chen Hongming Chief Scientific Officer | Exercise or conversion | +47,000 | $2.30 | $108K | 233,515 |
| 2021-02-25 | Chen Hongming Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −47,000 | 63,236 | ||
| 2021-01-04 | Brazzell Romulus K Chief Medical Officer | Grant or award | +27,500 | 303,996 | ||
| 2021-01-04 | Brazzell Romulus K Chief Medical Officer | Grant or award · Stock Option (right to buy) | +110,000 | 110,000 | ||
| 2021-01-04 | Chen Hongming Chief Scientific Officer | Grant or award | +22,666 | 186,515 | ||
| 2021-01-04 | Chen Hongming Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +90,667 | 90,667 | ||
| 2021-01-04 | Trachtenberg Eric | Grant or award | +22,666 | 128,567 | ||
| 2021-01-04 | Trachtenberg Eric | Grant or award · Stock Option (right to buy) | +90,667 | 90,667 | ||
| 2021-01-04 | Bazemore Todd Chief Operating Officer | Grant or award | +27,500 | 137,500 | ||
| 2021-01-04 | Bazemore Todd Chief Operating Officer | Grant or award · Stock Option (right to buy) | +110,000 | 110,000 |
Page 15 of 19 · 378 trades